Brief: Hansoh Pharmaceutical Entered Exclusive License & Collaboration Agreement With Silence Therapeutics
Oct 15 (Reuters) - Hansoh Pharmaceutical Group Company Ltd
3692.HK :
* ENTERED INTO AN EXCLUSIVE LICENSE AND COLLABORATION
AGREEMENT
WITH SILENCE THERAPEUTICS PLC
* SILENCE THERAPEUTICS WILL RECEIVE US$16 MILLION AS AN
UPFRONT
PAYMENT FROM CO
Source text for Eikon: ID:nHKS7k0sG1
Further company coverage: 3692.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Silence Therapeutics
See all newsBrief: Silence Therapeutics Reports Second Quarter 2025 Financial Results And Recent Business Highlights
Brief: Silence Therapeutics files for stock shelf, size not disclosed
Brief: Silence Therapeutics Announces Positive Results From Ongoing Sanreco Phase 1 Study
Brief: Silence Therapeutics Announces Positive Topline 48-Week Data From Phase 2 Study Of Zerlasiran In Patients With Elevated Lipoprotein
Brief: Silence Therapeutics PLC Files For Resale Of Up To 5.71 Million Shares By The Selling Securityholders - SEC Filing